about
Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials.Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD.Prophylaxis in older Canadian adults with hemophilia A: lessons and more questionsBleeding complications from the direct oral anticoagulants.The Influence of Socioeconomic Status on Selection of Anticoagulation for Atrial FibrillationCurrent status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies.Direct oral anticoagulants and the bleeding patient.The Anticoagulated trauma patient in the age of the direct oral anticoagulants: a Canadian perspective.Integrated multidisciplinary care for the management of chronic conditions in adults: an overview of reviews and an example of using indirect evidence to inform clinical practice recommendations in the field of rare diseases.Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients.Understanding stakeholder important outcomes and perceptions of equity, acceptability and feasibility of a care model for haemophilia management in the US: a qualitative study.Patterns of tertiary prophylaxis in Canadian adults with severe and moderately severe haemophilia B.Effect of moderate intensity exercise on haemostatic capacity in adults with haemophilia A and B: pilot study.The authors respond to "Is referral necessary for abnormal bleeding?"Successful immune tolerance induction with von Willebrand factor containing concentrate in an adult with haemophilia A and chronic inhibitor - a case study.A sticky situation: myocardial infarction in a young woman with immune thrombocytopenia on eltrombopag and a history of mediastinal radiation.A 24-year-old woman with heavy menstrual bleeding.Coagulation Testing in a Bleeding PatientHaemophilia commentary: The utility of BATsRetrospective review of Acquired Haemophilia A from the largest Canadian Haemophilia treatment centreThe safety and efficacy of ferumoxytol in the treatment of iron deficiency: a systematic review and meta-analysisBone health in symptomatic carriers of haemophilia A: a protocol for a multicentre prospective matched-cohort studyAcquired haemophilia A and concomitant factor XIII consumption
P50
Q33417304-ADF0F4C4-1C79-4D4B-AF74-7C86A6E6A45BQ35079761-E19E0E38-F09E-4468-8744-803DB1BFF144Q35091077-CC483BE6-D4A7-4655-9A7F-FE8F332C71A3Q35878677-08111A1D-562A-4CC6-9602-B2E953460CB3Q36620779-0258F15A-033F-423A-98A1-156C54D4E14AQ38085772-2FE55CDD-D1C4-4DBC-9206-91EDE5C80231Q38456829-070CF487-65D5-42B5-AAD2-E2F30E2B97A0Q38646206-C8916034-89D1-4292-AAEA-71B2773050B5Q38878434-88A2B5B1-FB0D-49C7-B663-B0A42DB4C83FQ38924389-65AEB024-F726-4C60-B37E-80FB8448693EQ40680110-C6E06D12-841E-4BC7-AC93-978EEC67FE50Q45862974-60AF4ADC-F93B-4EBE-9BB7-F9FDEF10DC26Q45863862-72414AD8-5FCC-4460-A5A8-11873DE6E052Q45874056-66E5E3CC-BFBC-435B-8017-0989D96756EEQ45882753-DFE901C9-2E27-443B-88DF-41C6EEB0C225Q48366304-C32F4F30-9AAD-4EF4-A764-0CC810DBB903Q55288281-9AE6C266-B61B-4353-8EFE-34EC1656F27DQ87809105-DDB09568-1A6F-492F-8831-35C0F9DB53FDQ88387269-92C2F2C4-99C6-4489-ABC7-636CC479DA85Q90971604-5C28D89A-6535-41E3-8F08-06C14391E37DQ91423856-957B63DC-6DF6-4B1C-A529-DA4AD8FB9700Q91654441-F1AB5736-2107-41A3-92A7-9EB57D3908B4Q92186642-0F327389-9FAB-43B8-A077-57AE0F35F092
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michelle Sholzberg
@ast
Michelle Sholzberg
@en
Michelle Sholzberg
@es
Michelle Sholzberg
@nl
type
label
Michelle Sholzberg
@ast
Michelle Sholzberg
@en
Michelle Sholzberg
@es
Michelle Sholzberg
@nl
prefLabel
Michelle Sholzberg
@ast
Michelle Sholzberg
@en
Michelle Sholzberg
@es
Michelle Sholzberg
@nl
P106
P1153
54986195200
P21
P31
P496
0000-0003-1220-0301